The multi-omic analysis platform for cancer research supports tumour profiling programmes that generate data across multiple omic layers simultaneously - somatic mutation data from WGS or targeted panels, gene expression changes from RNA-Seq, copy number profiles, methylation data, and, in some settings, proteomic and metabolomic datasets. The platform integrates those layers on shared patient and tumour identifiers, enabling pathway and network analysis across the full molecular landscape of the cancer in question. Common use cases include tumour subtype classification using multi-omic signatures, identification of co-occurring mutation and expression patterns in targeted cancer types, drug response biomarker discovery combining genomic and transcriptomic evidence, and cohort-level analysis for companion diagnostic development. The platform also supports rare disease genomics programmes that require multi-omic evidence to interpret variants of uncertain significance in the context of gene expression and protein abundance.A production-ready clinical bioinformatics pipeline must be reproducible across runs, scalable for clinical sample volumes, auditable for regulatory compliance, and integrated with clinical systems such as LIMS and reporting platforms.